Clinical Efficacy of Polymyxin B in Patients Infected with Carbapenem-Resistant Organisms

References

• Chamieh A, El-Hajj G, Zmerli O, et al. Carbapenem resistant organisms: a 9-year surveillance and trends at Saint George University Medical Center. J Infect Public Health. 2019;13(12):2101–2106. doi:10.1016/j.jiph.2019.02.01930956158
   PubMed Web of Science ®Google Scholar
• Fritzenwanker M, Imirzalioglu C, Herold S, et al. Treatment Options for Carbapenem- Resistant Gram-Negative Infections. Dtsch Arztebl Int. 2018;115(20–21):345–352. doi:10.3238/arztebl.2018.034529914612
   PubMed Web of Science ®Google Scholar
• Stansly PG, Schlosser ME. Studies on Polymyxin: isolation and Identification of Bacillus polymyxa and Differentiation of Polymyxin from Certain Known Antibiotics. J Bacteriol. 1947;54(5):549–556. doi:10.1128/JB.54.5.549-556.194716561391
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3):e02319–16. doi:10.1128/AAC.02319-1627993859
   PubMed Web of Science ®Google Scholar
• Zakuan ZD, Suresh K. Rational use of intravenous polymyxin B and colistin: a review. Med J Malaysia. 2018;73(5):351–359.30350826
   PubMedGoogle Scholar
• Aggarwal R, Dewan A. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17(1):15. doi:10.1186/s12941-018-0262-029571295
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Falci DR, Zavascki AP. Clinical Use of Polymyxin B. Adv Exp Med Biol. 2019;1145:197–218.31364080
   PubMed Web of Science ®Google Scholar
• Alves PH, Boff RT, Barth AL, et al. Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates. Diagn Microbiol Infect Dis. 2019;94(1):81–85. doi:10.1016/j.diagmicrobio.2018.11.01130638946
   PubMed Web of Science ®Google Scholar
• Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65. doi:10.1016/j.bjid.2018.12.00430796888
   PubMed Web of Science ®Google Scholar
• Dubrovskaya Y, Chen TY, Scipione MR, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2013;57(11):5394–5397. doi:10.1128/AAC.00510-1323959321
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55(12):5893–5899. doi:10.1128/AAC.00387-1121968368
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu W, Zhang Y, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter spp. from XiangYa Hospital, in Hunan Province, China. J Basic Microbiol. 2013;53(2):121–127. doi:10.1002/jobm.20110042022581767
   PubMed Web of Science ®Google Scholar
• Pan S, Huang X, Wang Y, et al. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control. 2018;7(1):8. doi:10.1186/s13756-018-0305-529387342
   PubMed Web of Science ®Google Scholar
• Cai Y, Leck H, Tan RW, et al. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study. Antibiotics. 2020;9(8):451. doi:10.3390/antibiotics9080451
   Web of Science ®Google Scholar
• Anania MC, Miranda C, Vizioli MG, et al. S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(10):E1591–600. doi:10.1210/jc.2013-165223928665
   PubMed Web of Science ®Google Scholar
• Dalyan CB, Topac T, Agca H, et al. Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates. Mikrobiyol Bul. 2018;52(1):35–48. doi:10.5578/mb.6399129642828
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.220930710469
   PubMed Web of Science ®Google Scholar
• Elias LS, Konzen D, Krebs JM, et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–2237. doi:10.1093/jac/dkq28520685752
   PubMed Web of Science ®Google Scholar
• Ismail B, Shafei MN, Harun A, et al. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect. 2018;51(6):763–769. doi:10.1016/j.jmii.2017.03.00728716359
   PubMedGoogle Scholar
• Vicari G, Bauer SR, Neuner EA, et al. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis. 2013;56(3):398–404. doi:10.1093/cid/cis90923090926
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Kawazoe Y, Kato S. Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study. J Intensive Care. 2017;5(1):19. doi:10.1186/s40560-017-0214-328239476
   PubMed Web of Science ®Google Scholar
• Komatsu M, Hachiya T, Takahashi H, et al. Direct hemoperfusion with polymyxin B-immobilized fiber for the treatment of the acute exacerbation of idiopathic pulmonary fibrosis in patients requiring invasive mechanical ventilation. Respir Investig. 2017;55(5):318–322. doi:10.1016/j.resinv.2017.05.001
   Google Scholar
• Koami H, Sakamoto Y, Miyasho T, et al. The effects of polymyxin B-immobilized fiber hemoperfusion on respiratory impairment in endotoxemic pigs. J Nippon Med Sch. 2014;81(3):130–138. doi:10.1272/jnms.81.13024998959
   PubMed Web of Science ®Google Scholar
• Guo W, Guo SC, Li M, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report. Antimicrob Resist Infect Control. 2018;7:22. doi:10.1186/s13756-018-0313-529456841
   PubMed Web of Science ®Google Scholar
• Zhang R, Cai JC, Zhou HW, et al. Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems. J Med Microbiol. 2011;60(Pt 12):1813–1819. doi:10.1099/jmm.0.025668-021835972
   PubMed Web of Science ®Google Scholar
• Rao GG, Ly NS, Diep J, et al. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. Int J Antimicrob Agents. 2016;48(3):331–336. doi:10.1016/j.ijantimicag.2016.06.00627449542
   PubMed Web of Science ®Google Scholar
• Manning N, Balabanian G, Rose M, et al. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. Microb Drug Resist. 2018;24(1):35–39. doi:10.1089/mdr.2016.029328590820
   PubMed Web of Science ®Google Scholar
• Nutman A, Lellouche J, Temkin E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26(9):1185–1191. doi:10.1016/j.cmi.2020.03.03532251844
   PubMed Web of Science ®Google Scholar
• Mattos KPH, Gouvea IR, Quintanilha JCF, et al. Polymyxin B clinical outcomes: a prospective study of patients undergoing intravenous treatment. J Clin Pharm Ther. 2019;44(3):415–419. doi:10.1111/jcpt.1280130666679
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis. 2009;65(4):431–434. doi:10.1016/j.diagmicrobio.2009.07.01819733029
   PubMed Web of Science ®Google Scholar
• Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med. 1973;56(1):31–35.4682585
   PubMedGoogle Scholar
• Suzuki T, Yamaguchi H, Ogura J, et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother. 2013;57(12):6319–6324. doi:10.1128/AAC.00254-1324100504
   PubMed Web of Science ®Google Scholar
• Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253–262. doi:10.2165/00128071-200102040-0000611705252
   PubMedGoogle Scholar